Chart: New Molecular Entities And Novel Therapeutic Biologics Approved In 2007
Executive Summary
New Molecular Entities And Novel Therapeutic Biologics Approved In 2007
You may also be interested in...
The Blockbuster Bubble: What is the Real Trend in R&D Output?
The years 1996 and 1997 were terrific for the biopharmaceutical industry, with record numbers of new product approvals. It is now clear, though, that they were outliers from the historic rates of new product flow. That fact has important implications: the products approved in those years are the blockbusters industry is still living on, and they supported massive infrastructure that Big Pharma now needs to shed.
Turning Back the Clock: Drug Approvals Hit 25 Year Low
You have to go back to 1983 to find a year as bad as 2007 for R&D output. It was a terrible year by any measure. The key question for industry: does it need to learn to subsist on a trickle of new drugs coming to market each year, or is the current drought in fact a sign of a transition to a new, more innovative R&D model? The sparse class of 2007 does offer some glimmers of hope.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011